πŸ›’ Your Cart

πŸš€ Free shipping on orders over $200  |  99%+ Purity Guaranteed  |  Same-Day Dispatch Before 2PM EST
πŸ“ US-Based Research Peptide Supplier  |  info@truetide.com
πŸ”¬ Oncology Research CAS: 881685-59-2 βœ“ 99%+ Purity

PNC-27
p53 Peptide β€” Selective Cancer Cell Research

β˜…β˜…β˜…β˜…β˜…4.8 / 5  Β·  Selective tumor cell membrane disruption

Select Size

$99
5mg
βœ“
99%+ purity, independently verified by HPLC & mass spectrometry
❄
Lyophilized vials β€” shipped with cold pack, stable at βˆ’20Β°C long term
πŸ“„
Certificate of Analysis included with every order
🚚
Same-day dispatch on orders before 2PM EST
πŸ”’
Discreet, unmarked packaging β€” research-grade handling
⚠️ For Research Use Only. PNC-27 is not approved for human consumption or therapeutic use. This product is sold exclusively as a research chemical for in vitro and laboratory research only.

What is PNC-27?

PNC-27 is a 32-amino acid peptide encompassing residues 17-26 of the p53 tumor suppressor protein's MDM-2 binding domain, fused to a cell membrane-penetrating leader sequence. It selectively interacts with HDM-2 (the human p53 homolog of MDM-2) expressed on the plasma membrane of cancer cells β€” a surface expression not found on normal cells. This selectivity makes PNC-27 a key research tool for cancer cell biology and targeted oncology studies.

CAS 881685-59-2 | 32 amino acids | p53 MDM-2 binding domain

HDM-2 Binding

Binds HDM-2 (overexpressed on tumor cell membranes) forming a complex that inserts into and disrupts the plasma membrane.

Membrane Pore Formation

HDM-2/PNC-27 complex creates transmembrane pores specifically in cancer cells, leading to rapid necrosis-like cell death.

Normal Cell Sparing

Non-cancerous cells lack surface HDM-2 expression and are not affected β€” establishing the selectivity basis for PNC-27 research.

Apoptosis-Independent

Cell death is necrotic/membrane disruption-based rather than apoptotic β€” important for research distinguishing p53-pathway from membrane integrity endpoints.

Original Selectivity Characterization

Bowne et al. demonstrated PNC-27 caused rapid, selective lysis of HDM-2-expressing human cancer cell lines (breast, pancreatic, leukemia) while sparing normal human mammary epithelial cells at the same concentration.

J Surg Res. 2009;163(2):260–268

Breast Cancer Cell Research

Weissler et al. confirmed PNC-27 killed breast cancer cells in vitro through HDM-2-mediated membrane pore formation, with cell death confirmed by FACS, LDH release, and EM ultrastructure.

Oncol Rep. 2010;23(1):69–76

Pancreatic Cancer Model

Administration in pancreatic tumor-bearing mice reduced tumor volume significantly vs control. Histology confirmed tumor cell necrosis without surrounding tissue damage.

Surgery. 2012;151(2):168–176

Research Protocol Dosing

In vitro studies use 50–200 Β΅M for 24–72 hours with cancer cell lines. In vivo tumor models use 5–15 mg/kg IP or intratumoral. Endpoints: LDH release (cytotoxicity), flow cytometry (annexin V/PI), confocal microscopy (membrane integrity), tumor volume measurement (caliper/imaging), and HDM-2 expression confirmation by immunofluorescence.

Research Note: Confirm HDM-2 surface expression in target cell line before using PNC-27 β€” selectivity depends on this expression. Include normal cell controls in every experiment.
Full NamePNC-27
CAS Number881685-59-2
Amino Acids32
Domainp53 residues 17-26 + leader sequence
TargetHDM-2 (surface-expressed)
Purityβ‰₯99% by HPLC
AppearanceWhite lyophilized powder
Storageβˆ’20Β°C, desiccated